Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event (AE) management algorithm in patients (pts) treated with adjuvant dabrafenib + trametinib (dab + tram): Primary results of COMBI-APlus.
Victoria Atkinson(Greenslopes Private Hospital), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Alexander M. Menzies(The University of Sydney), Flora Miranda(Novartis (United States)), Hiya Banerjee(Tris Pharma (United States)), Bettina Ryll(Stockholm School of Economics), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Jean‐Jacques Grob(Aix-Marseille Université), Mike Lau(Novartis (Switzerland)), Helen Gogas(National and Kapodistrian University of Athens), Caroline Robert(Institut Gustave Roussy), Avinash Gupta(Defence Institute of Physiology and Allied Sciences), Lev Demidov(Heidelberg University)
Cited by 9
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k